Reduced von Willebrand factor survival in type Vicenza von Willebrand disease.
Type Vicenza variant of von Willebrand disease (VWD) is characterized by a low plasma von Willebrand factor (VWF) level and supranormal VWF multimers. Two candidate mutations, G2470A and G3864A at exons 17 and 27, respectively, of the VWF gene were recently reported to be present in this disorder. Four additional families, originating from northeast Italy, with both mutations of type Vicenza VWD are now described. Like the original type Vicenza subjects, they showed a mild bleeding tendency and a significant decrease in plasma VWF antigen level and ristocetin cofactor activity but normal platelet VWF content. Unlike the original patients, ristocetin-induced platelet aggregation was found to be normal. Larger than normal VWF multimers were also demonstrated in the plasma. Desmopressin (DDAVP) administration increased factor VIII (FVIII) and VWF plasma levels, with the appearance of even larger multimers. However, these forms, and all VWF oligomers, disappeared rapidly from the circulation. The half-life of VWF antigen release and of elimination was significantly shorter than that in healthy counterparts, so that at 4 hours after DDAVP administration, VWF antigen levels were close to baseline. Similar behavior was demonstrated by VWF ristocetin cofactor activity and FVIII. According to these findings, it is presumed that the low plasma VWF levels of type Vicenza VWD are mainly attributed to reduced survival of the VWF molecule, which, on the other hand, is normally synthesized. In addition, because normal VWF-platelet GPIb interaction was observed before or after DDAVP administration, it is proposed that type Vicenza VWD not be considered a 2M subtype.
Casonato
Alessandra
A
Department of Medical and Surgical Sciences, University of Padua Medical School, Italy. sandra.casonato@unipd.it
Pontara
Elena
E
Sartorello
Francesca
F
Cattini
Maria Grazia
MG
Sartori
Maria Teresa
MT
Padrini
Roberto
R
Girolami
Antonio
A
D001792:Blood Platelets / Q000737:chemistry; D004252:DNA Mutational Analysis; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology; D004355:Drug Stability; D005169:Factor VIII / Q000032:analysis; D006207:Half-Life; D006801:Humans; D007558:Italy; D007700:Kinetics; D046911:Macromolecular Substances; D009154:Mutation; D010974:Platelet Aggregation / Q000187:drug effects; D012310:Ristocetin / Q000494:pharmacology; D014842:von Willebrand Diseases / Q000097:blood* / Q000235:genetics; D014841:von Willebrand Factor / Q000032:analysis / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism*
D046911:Macromolecular Substances; D014841:von Willebrand Factor; D012310:Ristocetin; D005169:Factor VIII; D003894:Deamino Arginine Vasopressin